Navigating the clinical impact of TROP2-targeting in NSCLC

touchSYMPOSIUM for touchONCOLOGY Listen to this touchSYMPOSIUM recorded live in March 2025 at the The European Lung Cancer Congress in Paris, France. Symposium chair Prof. Marina Garassino is joined by Prof. Jarushka Naidoo and Prof. David Planchard to explore the evolving role of TROP2-targeted ADCs in NSCLC.  Session 1: Prof. Marina Garassino highlights the emergence of TROP2 in NSCLC as a promising area of therapeutic innovation Session 2: Prof.  Jaruska Naidoo discusses the latest clinical trial findings for TROP2-targeting ADCs in NSCLC Session 3: Prof. David Planchard discusses the complexities of using TROP2 as a biomarker for patient selection Session 4: A panel discussion offering practical approaches for managing adverse effects associated with TROP2-targeted ADCs in clinical practice, with Q&A. This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from Daiichi Sankyo and AstraZeneca and is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchoncologyime.org/